He studied Medicine at the University of Munich, Harvard Medical School and Imperial College and obtained his research MD from the Institute of Immunology in Munich. He trained in General Medicine and Medical Oncology in Zurich and London and undertook post-doctoral research training in Zurich and at the CRUK London Research Institute.
In 2013, he joined the Royal Marsden Hospital as a Consultant in GI cancer and the Institute of Cancer Research as a research team leader. He was subsequently appointed as Chair in Gastrointestinal Cancer Medicine at St Bartholomew’s Hospital and Queen Mary University London in 2022. He is also the Director of GI Cancer Research at St Bartholomew’s Hospital. With his team, he develops precision medicine biomarkers and new immunotherapies and targeted therapies for early-stage and advanced or metastatic bowel, stomach and oesophageal cancers.
Professor Gerlinger is a member of scientific committees and working groups of the European Society of Medical Oncology, the American Society of Clinical Oncology and the American Association of Cancer Research.
- Colon and rectal cancer
- Stomach and oesophageal cancer
- Targeted therapy
- Personalised cancer medicine
Professor Marco Gerlinger does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.
Professor Marco Gerlinger does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.
Professor Marco Gerlinger does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.